Clinical trials
Prostate Cancer (Adenocarcinoma) clinical trials
Below are recruiting prostate cancer (adenocarcinoma) clinical trials, each written for real people, not researchers. We’re tracking 549 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06529549Recruiting
Organoid drug test for advanced prostate cancer
This trial uses a lab test on a tiny sample of your tumor (called an organoid) to find which drug might work best for your advanced prostate cancer. It's for men whose cancer has stopped responding to hormone therapy and got worse after first treatment.
Guangzhou, GuangdongAges 18–75 - NCT07723248RecruitingPhase 3
Oral Rinzimetostat for Advanced Prostate Cancer After Abiraterone
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
Coral Springs, FloridaAges 18 years+ - NCT06655259RecruitingPhase 2
TURP with standard therapy for metastatic prostate cancer
This trial tests whether adding a surgery called TURP (transurethral resection of the prostate) to the usual hormone therapy and chemotherapy can help men with metastatic prostate cancer that has spread to lymph nodes, bone, or other organs. The surgery helps relieve urinary symptoms and may improve how well the cancer responds to treatment.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07623941Recruiting
Focal Therapy Registry for Localized Prostate Cancer
This registry tracks men with early-stage prostate cancer who choose focal therapy—a targeted treatment that destroys only the cancer area while preserving healthy prostate tissue. The study helps doctors understand how well this approach works and its safety.
New York, New YorkAges 40–85 - NCT07621692RecruitingPhase 1
New radioactive therapy for advanced prostate cancer
This is an early-stage trial testing a new radioactive treatment (161Tb-PSMA) for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The treatment targets cancer cells using a radioactive metal that may be more effective than older similar treatments.
TaipeiAges 20 years+ - NCT07567521RecruitingPhase 1/Phase 2
TRC003 for Advanced Prostate Cancer That Has Progressed
This early-stage trial tests a new drug called TRC003 for men with advanced prostate cancer that has spread and stopped responding to standard treatments. The drug is designed to target cancer cells that show a specific marker called PSMA.
Taiyuan, ShanxiAges 18 years+ - NCT07568236RecruitingPhase 2
Fezolinetant for hot flushes in men on hormone therapy
This study tests whether fezolinetant can reduce hot flushes in men receiving hormone therapy (ADT) for prostate cancer. If you have bothersome hot flushes, this treatment may help lessen them.
ShatinAges 18 years+ - NCT06496581RecruitingPhase 3
Adding a targeted radiation drug for prostate cancer that hasn't responded well to initial treatment
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
AngersAges 18–80 - NCT07537010RecruitingPhase 1
3D1015 Injection for Advanced Prostate Cancer
This Phase 1 trial tests a new injectable treatment called 3D1015 for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. The drug is designed to target cancer cells using a special imaging marker that shows up on PET scans.
Wuxi, JiangsuAges 18 years+ - NCT06398613Recruiting
Using PSMA PET scan before prostate cancer surgery
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
OsloAges 18 years+ - NCT07474103Recruiting
Chemo, radiation, and immunotherapy for high-risk rectal cancer
This trial tests a treatment plan that combines chemotherapy, radiation, and an immunotherapy drug before surgery for people with high-risk locally advanced rectal cancer. The goal is to see if this approach can improve outcomes.
WuhanAges 18–75 - NCT03851640RecruitingPhase 3
Study drug for advanced prostate cancer that kept spreading despite standard treatments
This Phase 3 study tests HC-1119 soft capsules in men with metastatic castration-resistant prostate cancer—cancer that keeps progressing even when testosterone is blocked. It aims to see whether the drug works better than expected and is safe, especially after prior treatments like abiraterone and/or docetaxel.
ShanghaiAges 18 years+ - NCT07210086RecruitingPhase 2
PET scans to guide radiation for limited metastatic prostate cancer
This trial uses a special PET scan (POSLUMA) before and after radiation to see if it helps treat prostate cancer that has spread to a few spots outside the pelvis. It's for men whose cancer still responds to hormone therapy and who have not had widespread spread.
Duarte, CaliforniaAges 18 years+ - NCT07172685Recruiting
Triple therapy plus HIFU for high-tumor-burden prostate cancer
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
Jinan, ShandongAges 18 years+ - NCT07093866RecruitingPhase 2
Targeted drug combo for advanced prostate cancer
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Nanjing, JiangsuAges 18–75 - NCT06992232RecruitingPhase 2
Radiation or surgery plus hormone therapy for prostate cancer that has spread
This trial tests whether giving intense hormone therapy along with either radiation or surgery can help men with prostate cancer that has spread to a limited number of spots (10 or fewer) but not to organs like the liver or lungs. The goal is to treat both the main tumor and the visible metastatic spots more aggressively.
Nanjing, JiangsuAges 18–80 - NCT07007910RecruitingPhase 1
Study of HSK46575 for advanced prostate cancer
This trial tests a new drug, HSK46575, for men with metastatic castration-resistant prostate cancer that has worsened after hormone therapy and chemotherapy. The goal is to see if it can help slow the cancer's growth.
Chengdu, SichuanAges 18 years+ - NCT06943495RecruitingPhase 1
Personalized vs. standard dose of a targeted therapy for prostate cancer
This trial compares two ways of giving a radioactive drug (177Lu-PSMA-617) designed to find and destroy prostate cancer cells. It tests whether adjusting the dose based on your individual tumor’s activity works better than a fixed standard dose.
Québec, QuebecAges 18 years+ - NCT06941363Recruiting
Salvage radiotherapy for prostate cancer recurrence after surgery
This study tests a very short course of radiation given after prostate surgery, specifically for men whose PSA is rising again. The goal is to see if this approach can safely control the cancer.
Monza, ItalyAges 18–90 - NCT06831032Recruiting
Adaptive radiation for prostate cancer in lymph nodes
This trial tests a type of targeted radiation (SBRT) for prostate cancer that has come back only in certain lymph nodes around the belly or hip. The goal is to see if adapting the radiation plan during treatment can make the response last longer.
Toronto, OntarioAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Scottsdale, ArizonaAges 18–100 - NCT05802121RecruitingEarly Phase 1
Testing a gut bacteria supplement side effects during prostate hormone therapy
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
London, OntarioAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT05649943Recruiting
New prostate cancer treatment plus local therapy for metastatic cases
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Milan, LombardyAges 18 years+
Hear when a new Prostate Cancer (Adenocarcinoma) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer (adenocarcinoma)?
- Yes. Clin2 currently lists 549 recruiting prostate cancer (adenocarcinoma) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer (adenocarcinoma) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer (adenocarcinoma) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.